Filter by year
-
september142017
Newron reports half-year 2017 results
-
july112017
XADAGO® (SAFINAMIDE) NOW AVAILABLE IN THE U.S. FOR PARKINSON’S DISEASE PATIENTS
-
may172017
Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients Under 13 Years of Age
-
may122017
Newron Receives EUR11.3m Milestone Payments for US Approval of Xadago® (safinamide)
-
april112017
Valeo Pharma and Zambon form partnership for Parkinson’s disease treatment Xadago® (safinamide) in Canada
-
april102017
ZAMBON LAUNCHES XADAGO® (safinamide) IN PORTUGAL For patients With mid- to late-stage Parkinson’s Disease
-
april52017
Meiji Seika and Eisai enter into a collaboration for the development and commercialization of safinamide in Parkinson’s disease for Japan and Asia
-
march282017
Newron Shareholders Confirm Company Management
-
march252017
Newron presents encouraging detailed results of its Phase IIa study with Evenamide in patients with schizophrenia
-
march212017
FDA APPROVES XADAGO® (SAFINAMIDE) FOR PARKINSON’S DISEASE (PD) PATIENTS
-
march162017
Newron to Present at the 16th International Congress on Schizophrenia Research
-
march22017
Newron announces 2016 financial results and provides outlook for 2017 Board approves agenda for AGM on March 28, 2017
-
february212017
Newron Supports Global Rare Disease Day® 2017 and Rett Syndrome Studies
-
january102017
Seqirus and Zambon enter into a partnership for Parkinson’s disease product in Australia and New Zealand
-
january32017
Evenamide met study objectives of good tolerability, safety, and preliminary evidence of efficacy as an add-on therapy for the treatment of schizophrenia- unique MoA